US EditionPublished • loading... • Updated
Sanofi expects vaccine sales growth to dip amid ‘challenging environment’
Sanofi expects 2.5% vaccine sales drop in Q4 2025 and slight decline in 2026 due to U.S. policy shifts reducing immunization rates, despite strong flu shot sales.
Summary by biopharmadive.com
8 Articles
8 Articles
Driven by the success of Dupixent and the rise of its new medicines, the giant Sanofi plans to buy shares of one billion euros and aims for solid and profitable growth over several years.
Sanofi's best selling, the Dupixent still benefits from several years of exclusivity in the market. While the strategy of the French laboratory to manage after Dupixent regularly raises questions among investors, Sanofi's leader, Paul Hudson, wanted to be reassuring... without detailing the method.
https://www.tradingsat.com/sanofi-EN0000120578/actualites/sanofi-en-chute-de-24-sur-un-an-en-bourse-sanofi-soigne-une-neuve-nis-sa-rentabilite-en-son-blockbuster-dupixent-1155385.html
Coverage Details
Total News Sources8
Leaning Left0Leaning Right1Center2Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
